Physician profile
Theodore Nukes
NPI 1891766739
$893.54
in general payments reported to CMS, 2019-2025
27 companies · $441 in 2025
The $441 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $270 · 2021: $25.25 · 2022: $20.06 · 2024: $137 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $578.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $93.64 | 2019-2025 | Briviact, Zilbrysq |
| Pfizer INC. | $91.17 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $82.96 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $68.92 | 2025 | Crexont |
| Teva Pharmaceuticals USA, INC. | $61.11 | 2019-2025 | Austedo Xr |
| Amgen INC. | $45.87 | 2019 | |
| Lundbeck LLC | $42.66 | 2024 | Vyepti |
| Mallinckrodt Hospital Products INC. | $32.47 | 2024 | Acthar |
| Biogen, INC. | $32.25 | 2019-2025 | Tysabri, Vumerity |
| Abbvie INC. | $29.42 | 2021-2025 | |
| Sk Life Science, INC. | $26.65 | 2025 | |
| Vanda Pharmaceuticals INC. | $26.22 | 2025 | Ponvory |
| Abbott Laboratories | $22.86 | 2025 | Proclaim |
| Livanova USA, INC. | $22.79 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Companion Medical, INC. | $21.57 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $21.30 | 2019 | |
| Ani Pharmaceuticals, INC. | $18.98 | 2025 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $17.71 | 2019 | |
| Argenx US, INC. | $17.41 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Insightec,INC | $17.16 | 2025 | Exablate |
| Axsome Therapeutics, INC. | $16.68 | 2025 | Symbravo |
| Genentech USA, INC. | $16.56 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.22 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.29 | 2019 | |
| Mannkind Corporation | $13.11 | 2019 | |
| Zogenix INC. | $12.60 | 2021 | |
| Lilly USA, LLC | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Nukes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.